Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies

被引：39

作者：

Bahrami, Afsane ^{[1
]}

Khazaei, Majid ^{[2
,3
]}

Bagherieh, Fariba ^{[1
]}

Ghayour-Mobarhan, Majid ^{[4
]}

Maftouh, Mina ^{[4
]}

Hassanian, Seyed Mahdi ^{[4
,5
]}

Avan, Amir ^{[4
,6
]}

机构：

[1] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran

[2] Mashhad Univ Med Sci, Neurogen Inflammatory Res Ctr, Mashhad, Iran

[3] Mashhad Univ Med Sci, Dept Physiol, Mashhad, Iran

[4] Mashhad Univ Med Sci, Sch Med, Metab Syndrome Res Ctr, Mashhad, Iran

[5] Mashhad Univ Med Sci, Sch Med, Dept Med Biochem, Mashhad, Iran

[6] Mashhad Univ Med Sci, Sch Med, Canc Res Ctr, Mashhad, Iran

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2017年 / 232卷 / 11期

关键词：

desmoplastic reaction; pancreatic cancer; pancreatic stellate cells; stroma; PHASE-II TRIAL; DUCTAL ADENOCARCINOMA; STELLATE CELLS; EXTRACELLULAR-MATRIX; TUMOR-STROMA; MONOCLONAL-ANTIBODY; IMMUNE ACTIVATION; GROWTH-FACTOR; EXPRESSION; FIBROSIS;

D O I：

10.1002/jcp.25798

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Desmoplasia or abundant fibrotic stroma is a typical property of most malignancies, which has a great effect on tumorigenesis, angiogenesis, and resistance to therapy. The activated stroma cells comprises several cell types including endothelial cells, nerve cells, inflammatory/macrophages cells, stellate cells, and extracellular matrix. In other word, the interactions of cancer-stroma modulate tumorigenesis, therapy resistance, and poor delivery of drugs. Therefore, targeting the tumor stroma in combination with conventional chemotherapeutic agents could provide a promising approach in the treatment of pancreatic cancer. This review summarizes the current knowledge about pancreatic stellate cells, targeting stroma compartments with particular emphasis on preclinical, and clinical trials on targeting of stroma as an option in pancreatic cancer treatment.

引用

页码：2931 / 2937

页数：7

共 50 条

[21] Pancreatic cancer stroma: an update on therapeutic targeting strategies
Abdel N. Hosein
Rolf A. Brekken
Anirban Maitra
Nature Reviews Gastroenterology & Hepatology, 2020, 17 : 487 - 505
[22] Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, Minela
Shahbazi, Reza
Ulubayram, Kezban
Ozpolat, Bulent
ANTICANCER RESEARCH, 2018, 38 (12) : 6591 - 6606
[23] Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises
Sledge, George W., Jr.
Jotwani, Aparna C.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 669 - +
[24] The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer
Huang, Huocong
Brekken, Rolf A.
CANCER RESEARCH, 2019, 79 (02) : 328 - 330
[25] Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Neesse, Albrecht
Krug, Sebastian
Gress, Thomas M.
Tuveson, David A.
Michl, Patrick
ONCOTARGETS AND THERAPY, 2014, 7 : 33 - 43
[26] Stroma A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors
Gu, Jichun
Saiyin, Hexige
Fu, Deliang
Li, Ji
PANCREAS, 2018, 47 (04) : 382 - 389
[27] Targeting targeted therapies
Shingler, William
Harrop, Richard
IMMUNOTHERAPY, 2010, 2 (06) : 745 - 748
[28] Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer
Cinar, Pelin
Tempero, Margaret A.
CANCER JOURNAL, 2012, 18 (06): : 653 - 664
[29] Advanced or Metastatic Pancreatic Cancer: Molecular Targeted Therapies
Bayraktar, Soley
Rocha-Lima, Caio M.
MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (06): : 606 - 619
[30] Pancreatic cancer treatment with targeted therapies: are we there yet?
Nwaefulu, O. Ngozi
Sagineedu, S. Rao
Islam, M. Kaisarul
Stanslas, J.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (02) : 367 - 381

← 1 2 3 4 5 →